Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention

Pharmacological Research

Volumn 100, Issue , 2015, Pages 135-147

  Cao, Martine ^a   Onyango, Evans O ^b   Williams, Charlotte R ^a   Royce, Darlene B ^a   Gribble, Gordon W ^b   Sporn, Michael B ^a   Liby, Karen T ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Lamont Doherty Earth Observatory   (United States)

Author keywords

CDDO Imidazolide; Chemopreventiona; HO 1; Lung carcinogenesis; Nitric oxide; NQO1; Nrf2; Pyridyl analogues; Vinyl carbamate

Indexed keywords

1 [2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OYL] 4 (PYRIDIN 2 YL) 1H IMIDAZOLE; 1 [2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OYL] 4 (PYRIDIN 3 YL) 1H IMIDAZOLE; ANTINEOPLASTIC AGENT; HEME OXYGENASE 1; IMIDAZOLE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; 1-(2-CYANO-3,12-DIOXOOLEANA-1,9-DIEN-28-OYL) IMIDAZOLE; HMOX1 PROTEIN, HUMAN; NOS2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; OLEANOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY; LIVER; LUNG; LUNG CARCINOGENESIS; LUNG CARCINOMA; MACROPHAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAW264.7 CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TISSUE DISTRIBUTION; U937 CELL LINE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; DRUG EFFECTS; HUMAN; METABOLISM; NEOPLASMS; TUMOR CELL LINE; U-937 CELL LINE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; HEME OXYGENASE-1; HUMANS; IMIDAZOLES; MICE; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE II; OLEANOLIC ACID; OXIDATIVE STRESS; RNA, MESSENGER; U937 CELLS;

EID: 84939236390     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.07.024     Document Type: Article

References (42)

1. A.E. Place, N. Suh, C.R. Williams, R. Risingsong, T. Honda, Y. Honda, G.W. Gribble, L.M. Leesnitzer, J.B. Stimmel, T.M. Willson, E. Rosen, and M.B. Sporn The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo Clin. Cancer Res. 9 2003 2798 2806
2. K.T. Liby, and M.B. Sporn Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease Pharmacol. Rev. 64 2012 972 1003
3. K. Liby, T. Hock, M.M. Yore, N. Suh, A.E. Place, R. Risingsong, C.R. Williams, D.B. Royce, T. Honda, Y. Honda, G.W. Gribble, N. Hill-Kapturczak, A. Agarwal, and M.B. Sporn The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling Cancer Res. 65 2005 4789 4798
4. M.S. Yates, M. Tauchi, F. Katsuoka, K.C. Flanders, K.T. Liby, T. Honda, G.W. Gribble, D.A. Johnson, J.A. Johnson, N.C. Burton, T.R. Guilarte, M. Yamamoto, M.B. Sporn, and T.W. Kensler Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes Mol. Cancer Ther. 6 2007 154 162
5. M.S. Yates, Q.T. Tran, P.M. Dolan, W.O. Osburn, S. Shin, C.C. McCulloch, J.B. Silkworth, K. Taguchi, M. Yamamoto, C.R. Williams, K.T. Liby, M.B. Sporn, T.R. Sutter, and T.W. Kensler Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice Carcinogenesis 30 2009 1024 1031
6. K. Liby, N. Voong, C.R. Williams, R. Risingsong, D.B. Royce, T. Honda, G.W. Gribble, M.B. Sporn, and J.J. Letterio The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells Clin. Cancer Res. 12 2006 4288 4293
7. M.M. Yore, A.N. Kettenbach, M.B. Sporn, S.A. Gerber, and K.T. Liby Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR PLoS One 6 2011 e22862
8. M.S. Yates, M.K. Kwak, P.A. Egner, J.D. Groopman, S. Bodreddigari, T.R. Sutter, K.J. Baumgartner, B.D. Roebuck, K.T. Liby, M.M. Yore, T. Honda, G.W. Gribble, M.B. Sporn, and T.W. Kensler Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole Cancer Res. 66 2006 2488 2494
9. J.Y. So, J.J. Lin, J. Wahler, K.T. Liby, M.B. Sporn, and N. Suh A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer PLoS One 9 2014 e107616
10. N.M. Johnson, P.A. Egner, V.K. Baxter, M.B. Sporn, R.S. Wible, T.R. Sutter, J.D. Groopman, T.W. Kensler, and B.D. Roebuck Complete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold Cancer Prev. Res. 7 2014 658 665
11. T. Honda, Y. Honda, F.G. Favaloro Jr., G.W. Gribble, N. Suh, A.E. Place, M.H. Rendi, and M.B. Sporn A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production Bioorg. Med. Chem. Lett. 12 2002 1027 1030
12. K.M. Lancaster, J.B. Gerken, A.C. Durrell, J.H. Palmer, and H.B. Gray Electronic structures, photophysical properties, and electrochemistry of ruthenium(II)(bpy)(2) pyridylimidazole complexes Coord. Chem. Rev. 254 2010 1803 1811
13. H. Yamadaand, and T. Okamoto Formamide reactions. I, Reaction with alkyl halides, alkyl formates and alcohols (author's transl.) Yakugaku Zasshi: J. Pharm. Soc. Jpn. 95 1975 487 492
14. K. Liby, R. Risingsong, D.B. Royce, C.R. Williams, T. Ma, M.M. Yore, and M.B. Sporn Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice Cancer Prev. Res. 2 2009 1050 1058
15. N. Suh, T. Honda, H.J. Finlay, A. Barchowsky, C. Williams, N.E. Benoit, Q.W. Xie, C. Nathan, G.W. Gribble, and M.B. Sporn Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages Cancer Res. 58 1998 717 723
16. T.D. Schmittgenand, and K.J. Livak Analyzing real-time PCR data by the comparative C(T) method Nature Protoc. 3 2008 1101 1108
17. H.J. Prochaskaand, and A.B. Santamaria Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers Anal. Biochem. 169 1988 328 336
18. K. Liby, D.B. Royce, C.R. Williams, R. Risingsong, M.M. Yore, T. Honda, G.W. Gribble, E. Dmitrovsky, T.A. Sporn, and M.B. Sporn The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice Cancer Res. 67 2007 2414 2419
19. C. Nathanand, and A. Ding Nonresolving inflammation Cell 140 2010 871 882
20. K.D. Kroncke, K. Fehsel, and V. Kolb-Bachofen Inducible nitric oxide synthase in human diseases Clin. Exp. Immun. 113 1998 147 156
21. R. Zamora, Y. Vodovotz, and T.R. Billiar Inducible nitric oxide synthase and inflammatory diseases Mol. Med. 6 2000 347 373
22. M. Lechner, P. Lirk, and J. Rieder Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin Sem. Cancer Biol. 15 2005 277 289
23. K.T. Liby, D.B. Royce, R. Risingsong, C.R. Williams, A. Maitra, R.H. Hruban, and M.B. Sporn Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer Cancer Prev. Res. 3 2010 1427 1434
24. C. To, C.S. Ringelberg, D.B. Royce, C.R. Williams, R. Risingsong, M.B. Sporn, and K.T. Liby Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis Carcinogenesis 36 2015 769 781
25. M. Liu, N.M. Reddy, E.M. Higbee, H.R. Potteti, S. Noel, L. Racusen, T.W. Kensler, M.B. Sporn, S.P. Reddy, and H. Rabb The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice Kidney Int. 85 2014 134 141
26. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, E.B. Grossman, M. Krauth, S. Ruiz, P. Audhya, H. Christ-Schmidt, J. Wittes, and D.G. Warnock BEAM Study Investigators, Bardoxolone methyl and kidney function in CKD with type 2 diabetes N. Engl. J. Med. 365 2011 327 333
27. J. Alam, D. Stewart, C. Touchard, S. Boinapally, A.M. Choi, and J.L. Cook Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 274 1999 26071 26078
28. T.W. Kensler, N. Wakabayashi, and S. Biswal Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway Ann. Rev. Pharmacol. Toxicol. 47 2007 89 116
29. A.T. Dinkova-Kostovaand, and P. Talalay NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector Arch. Biochem. Biophys. 501 2010 116 123
30. X. Yuand, and T. Kensler Nrf2 as a target for cancer chemoprevention Mutat. Res. 591 2005 93 102
31. B.S. Cornblatt, L. Ye, A.T. Dinkova-Kostova, M. Erb, J.W. Fahey, N.K. Singh, M.S. Chen, T. Stierer, E. Garrett-Mayer, P. Argani, N.E. Davidson, P. Talalay, T.W. Kensler, and K. Visvanathan Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast Carcinogenesis 28 2007 1485 1490
32. S.S. Hecht, F. Kassie, and D.K. Hatsukami Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers Nat. Rev. Cancer 9 2009 476 488
33. H. Lu, W. Ouyang, and C. Huang Inflammation, a key event in cancer development Mol. Cancer Res. 4 2006 221 233
34. M.L. Hyer, R. Shi, M. Krajewska, C. Meyer, I.V. Lebedeva, P.B. Fisher, and J.C. Reed Apoptotic activity and mechanism of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic-acid and related synthetic triterpenoids in prostate cancer Cancer Res. 68 2008 2927 2933
35. A. Bishayee, S. Ahmed, N. Brankov, and M. Perloff Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer Front. Biosci. 16 2011 980 996
36. F. Zhang, S. Wang, M. Zhang, Z. Weng, P. Li, Y. Gan, L. Zhang, G. Cao, Y. Gao, R.K. Leak, M.B. Sporn, and J. Chen Pharmacological induction of heme oxygenase-1 by a triterpenoid protects neurons against ischemic injury Stroke J. Cerebral Circ. 43 2012 1390 1397
37. T.E. Sussan, T. Rangasamy, D.J. Blake, D. Malhotra, H. El-Haddad, D. Bedja, M.S. Yates, P. Kombairaju, M. Yamamoto, K.T. Liby, M.B. Sporn, K.L. Gabrielson, H.C. Champion, R.M. Tuder, T.W. Kensler, and S. Biswal Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice Proc. Natl. Acad. Sci. U.S.A. 106 2009 250 255
38. N.M. Reddy, V. Suryanaraya, M.S. Yates, S.R. Kleeberger, P.M. Hassoun, M. Yamamoto, K.T. Liby, M.B. Sporn, T.W. Kensler, and S.P. Reddy The triterpenoid CDDO-imidazolide confers potent protection against hyperoxic acute lung injury in mice Am. J. Resp. Critic. Care Med. 180 2009 867 874
39. N. Nagai, R.K. Thimmulappa, M. Cano, M. Fujihara, K. Izumi-Nagai, X. Kong, M.B. Sporn, T.W. Kensler, S. Biswal, and J.T. Handa Nrf2 is a critical modulator of the innate immune response in a model of uveitis Free Radical Biol. Med. 47 2009 300 306
40. A.E. Nassar, A.M. Kamel, and C. Clarimont Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability Drug Discovery Today 9 2004 1020 1028
41. J.H. Linand, and A.Y. Lu Role of pharmacokinetics and metabolism in drug discovery and development Pharmacol. Rev. 49 1997 403 449
42. I.M. Kapetanovic, R. Krishnaraj, T. Martin-Jimenez, L. Yuan, R.B. van Breemen, and A. Lyubimov Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics Chem. Biol. Interact. 164 2006 68 75